Lineage Cell Therapeutics LCTX Institutional Ownership

Updated Oct 11, 2026

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) was held by 131 institutional investors that filed 13F reports for the quarter ended June 30, 2026.

• Together they owned 44.10% of the outstanding stock in Q2 2026, down from 44.79% a quarter earlier.
• Total shares held in LCTX fell 0.13% from Q1 2026; the number of holders rose 3.97% from Q2 2025.
• Among the 131 holders of Lineage Cell Therapeutics, 62 added to their positions, 27 reduced their stakes and 42 left their positions unchanged.
• Institutional investors held 111.53Mn shares of Lineage Cell Therapeutics in total at the end of Q2 2026, down 143.66K from the prior quarter and up 14.79Mn from a year earlier.
• Broadwood Capital Inc held the largest position in LCTX at 49.56Mn shares as of June 30, 2026, or 19.60% of shares outstanding.
• The largest position increases in LCTX for Q2 2026 were by BlackRock, Inc. (+9.32Mn shares), Geode Capital Management, LLC (+2.78Mn shares), State Street Corp (+1.22Mn shares), Northern Trust Corp (+1.16Mn shares) and Vanguard Capital Management LLC (+736.23K shares).
• The largest position reductions in LCTX for Q2 2026 were by Millennium Management LLC (-2.54Mn shares), Marshall Wace, LLP (-1.78Mn shares), Susquehanna International Group, LLP (-1.24Mn shares), Jane Street Group, LLC (-943.42K shares) and Renaissance Technologies LLC (-780.27K shares).
• Lineage Cell Therapeutics' 10 largest institutional shareholders as of Q2 2026 were Broadwood Capital Inc (49.56Mn shares), BlackRock, Inc. (13.19Mn shares), Vanguard Capital Management LLC (9.05Mn shares), Defender Capital, LLC (6.6Mn shares), Geode Capital Management, LLC (5.3Mn shares), Fifth Third Bancorp (4.6Mn shares), Millennium Management LLC (3.02Mn shares), State Street Corp (2.31Mn shares), Vanguard Fiduciary Trust Co (1.67Mn shares) and Northern Trust Corp (1.66Mn shares), per Business Quant data.